Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition

ABSTRACT: Targeted next-generation sequencing was performed in patients with IDH1 or IDH2 mutations. Here we describe 4 cases where mutant IDH isoform switching serves as a mechanism of acquired clinical resistance to mutant IDH inhibition.

INSTRUMENT(S): Illumina MiSeq

ORGANISM(S): Homo Sapiens

SUBMITTER: Memorial Sloan Kettering Cancer Center

PROVIDER: PRJEB29344 | EVA | 2018-10-24

REPOSITORIES: EVA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	merged_final.vcf.gz	Vcf
	merged_final.vcf.gz.tbi	Vcf

Items per page:

1 - 2 of 2

Similar Datasets

E-GEOD-69556

Project description:Next Generation Sequencing of PKD2 mutant mice kidneys

2019-05-14 | E-GEOD-69556 | ExpressionAtlas

E-GEOD-118498

Project description:Next Generation Sequencing Facilitates Quantitative Analysis of WT and dek42 mutant Transcriptomes

2020-04-06 | E-GEOD-118498 | ExpressionAtlas

E-GEOD-113048

Project description:Next Generation Sequencing Facilitates Quantitative Analysis of WT and zmbzip22 mutant Transcriptomes

2020-04-06 | E-GEOD-113048 | ExpressionAtlas

E-GEOD-97422

Project description:Next Generation Sequencing Facilitates Quantitative Analysis of WT and o11 mutant Transcriptomes

2020-04-06 | E-GEOD-97422 | ExpressionAtlas

E-GEOD-120674

Project description:Next Generation Sequencing Facilitates Quantitative Analysis of WT and dek15 mutant Transcriptomes

2020-04-06 | E-GEOD-120674 | ExpressionAtlas

Plasmodium falciparum assocation study of artemisinin resistance

Project description:A testing association of parasite genotypes with clinical resistance phenotype. Submission of genotypes from all microarray genotyped samples Comparison of DNA from clinical isolates and generated by next-generation sequencing with prolonged clearance half-life

2014-05-28 | E-GEOD-56390 | biostudies-arrayexpress

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

Project description:Targeted next-generation sequencing was performed in patients with IDH2-mutant acute myeloid leukemia to identify genomic mechanisms of primary or acquired resistance to the mutant IDH2 inhibitor enasidenib.

2018-04-20 | PRJEB26337 | EVA

E-GEOD-60424

Project description:Next generation sequencing of human immune cell subsets across diseases

2025-01-24 | E-GEOD-60424 | ExpressionAtlas

Spectrum, clinical correlates and clinical implications of BRAF-inhibitor resistance mechanisms in melanoma

Project description:Multiple BRAF inhibitor resistance mechanisms have been described, however their relative frequency, clinical correlates, and effect on subsequent therapy have not been assessed in patients with metastatic melanoma. Excised progressing BRAFV600 mutant melanoma metastases (Prog) from patients treated with dabrafenib (n=22) or vemurafenib (n=8) were analyzed for known resistance mechanisms. Oncogenic signaling in Prog and matched pre-treatment tumors was examined using gene expression analysis. Resistance mechanisms were correlated with clinicopathologic features and outcome. A resistance mechanism was identified in 21/38 (55%) Prog samples from 30 patients; BRAF splice variants (n=12, 32%), N-RAS mutations (n=3, 8%), BRAF amplification (n=3, 8%), MEK1/2 mutations (n=3, 8%) and an AKT1 mutation (n=1, 3%). Four Progs tumours displayed multiple resistance mechanisms, and four patients with multiple Progs demonstrated inter-tumoral heterogeneity of resistance mechanisms. Six (21%) of 29 Progs showed loss of MAPK activity by gene expression analysis. These MAPK-inhibited Progs had unknown resistance mechanisms, and these patients had a shorter progression-free survival than patients with MAPK re-activated Progs. There were no responses to subsequent targeted therapy, even when the identified mechanism of resistance was predicted to be responsive. Heterogeneity of resistance mechanisms was common between patients, within patients and within individual tumors. The MAPK pathway remained inhibited in a subset of resistant tumors with unknown mechanisms of resistance, and the outcomes of patients with these tumors are poor. The use of sequential targeted therapies based on the molecular characteristics of a single progressing biopsy is unlikely to provide improved clinical outcomes. Total RNA was obtained from fresh-frozen melanoma tumour samples from patients before commencing treatment with dabrafenib or vemurafenib and at time of tumour progression.

2014-02-19 | E-GEOD-50509 | biostudies-arrayexpress

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Project description:Acquired drug resistance to tyrosine kinase inhibitor (TKI) targeted therapies remains a major clinical challenge. In EGFR mutant non-small cell lung cancer (NSCLC), therapeutic failure of EGFR TKIs can result from both genetic and epigenetic mechanisms of acquired drug resistance. Histologic and gene expression changes consistent with an epithelial-to-mesenchymal transition (EMT) have been associated with resistance to EGFR TKIs in both experimental models and in patients, and may coincide with genetic mechanisms of resistance such as the EGFRT790M gatekeeper mutation. While therapeutic approaches targeting EGFRT790M have been developed, a strategy for overcoming EMT-related resistance remains unclear. We performed whole-genome CRISPR screening on patient-derived, mesenchymal EGFRT790M-positive cell lines and identified FGFR1 as a critical gene promoting resistance to third generation EGFR TKIs. The FGFR1-3 inhibitor, BGJ398 (infigratinib), resensitized resistant mesenchymal-like cell lines to EGFR inhibition in a synergistic manner. Combining EGFR + FGFR inhibitors also inhibited the in vitro survival and expansion of EGFR mutant drug tolerant cells with mesenchymal-like features prior to the development of drug resistance, and delayed the development of in vivo resistance in EGFR mutant NSCLC xenograft tumors. These results suggest that dual EGFR + FGFR blockade may be a promising clinical strategy for preventing and overcoming EMT-associated acquired drug resistance in EGFR mutant NSCLC.

2019-04-30 | GSE114647 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data